Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Fish

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine|November 3, 2005
Exception from informed consent: viewpoint of institutional review boards--balancing risks to subjects, community consultation, and future directionsAmy A Ernst, Susan Fish
Journal of Empirical Research on Human Research Ethics : JERHRE|April 24, 2009
Variability in institutional approaches to ethics review of community-based research conducted in collaboration with unaffiliated organizationsMichael Silverstein, Mary Banks, Susan Fish, et al.
BMC Musculoskeletal Disorders|April 30, 2003
Does simvastatin stimulate bone formation in vivo?Dietrich von Stechow, Susan Fish, Dror Yahalom, et al.
Targeted Oncology|January 7, 2015
Effectiveness and safety of post-induction phase bevacizumab treatment for patients with non-small-cell lung cancer: results from the ARIES observational cohort studyMichael P Kosty, Antoinette J Wozniak, Mohammad Jahanzeb, et al.
The Oncologist|June 7, 2023
The Value of Pharmaceutical Industry-Sponsored Patient Registries in Oncology Clinical ResearchE Dawn Flick, Howard R Terebelo, Susan Fish, et al.
Pharmacoepidemiology and Drug Safety|January 11, 2016
Effectiveness of bevacizumab exposure beyond disease progression in patients with non-small-cell lung cancer: analyses of the ARIES observational cohort studyLarry Leon, Michael Kosty, Mohammad Jahanzeb, et al.
Assay and Drug Development Technologies|April 20, 2004
Development of a high-throughput assay for two inositol-specific phospholipase Cs using a scintillation proximity formatMichael E Bembenek, Sadhana Jain, Andrea Prack, et al.
Pharmacoepidemiology and Drug Safety|May 17, 2014
Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort studyAxel Grothey, E Dawn Flick, Allen L Cohn, et al.
The Oncologist|September 28, 2012
Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort studyJohanna C Bendell, Tanios S Bekaii-Saab, Allen L Cohn, et al.
Journal of Medicinal Chemistry|June 2, 2012
Diazine indole acetic acids as potent, selective, and orally bioavailable antagonists of chemoattractant receptor homologous molecule expressed on Th2 cells (CRTH2) for the treatment of allergic inflammatory diseasesNeelu Kaila, Adrian Huang, Alessandro Moretto, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine|November 3, 2005
Exception from informed consent: viewpoint of institutional review boards--balancing risks to subjects, community consultation, and future directionsAmy A Ernst, Susan Fish
Journal of Empirical Research on Human Research Ethics : JERHRE|April 24, 2009
Variability in institutional approaches to ethics review of community-based research conducted in collaboration with unaffiliated organizationsMichael Silverstein, Mary Banks, Susan Fish, et al.
BMC Musculoskeletal Disorders|April 30, 2003
Does simvastatin stimulate bone formation in vivo?Dietrich von Stechow, Susan Fish, Dror Yahalom, et al.
Targeted Oncology|January 7, 2015
Effectiveness and safety of post-induction phase bevacizumab treatment for patients with non-small-cell lung cancer: results from the ARIES observational cohort studyMichael P Kosty, Antoinette J Wozniak, Mohammad Jahanzeb, et al.
The Oncologist|June 7, 2023
The Value of Pharmaceutical Industry-Sponsored Patient Registries in Oncology Clinical ResearchE Dawn Flick, Howard R Terebelo, Susan Fish, et al.
Pharmacoepidemiology and Drug Safety|January 11, 2016
Effectiveness of bevacizumab exposure beyond disease progression in patients with non-small-cell lung cancer: analyses of the ARIES observational cohort studyLarry Leon, Michael Kosty, Mohammad Jahanzeb, et al.
Assay and Drug Development Technologies|April 20, 2004
Development of a high-throughput assay for two inositol-specific phospholipase Cs using a scintillation proximity formatMichael E Bembenek, Sadhana Jain, Andrea Prack, et al.
Pharmacoepidemiology and Drug Safety|May 17, 2014
Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort studyAxel Grothey, E Dawn Flick, Allen L Cohn, et al.
The Oncologist|September 28, 2012
Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort studyJohanna C Bendell, Tanios S Bekaii-Saab, Allen L Cohn, et al.
Journal of Medicinal Chemistry|June 2, 2012
Diazine indole acetic acids as potent, selective, and orally bioavailable antagonists of chemoattractant receptor homologous molecule expressed on Th2 cells (CRTH2) for the treatment of allergic inflammatory diseasesNeelu Kaila, Adrian Huang, Alessandro Moretto, et al.
Pageof 2